Optimally, vaccination of eligible adults should occur before the onset of increased RSV activity in the community. The timing of the onset, peak, and decline of RSV activity varies from one year to the next; however, because the vaccine’s protection in older adults lasts at least 2 seasons, if you have the opportunity to vaccinate during the summer, you might choose to give it if you are concerned that you may not have the opportunity later in the fall.
Ask the Experts: Respiratory syncytial virus (RSV): Scheduling & Documentation (Vaccines and Antibody)
Aim for nirsevimab administration in the first week of life for infants born shortly before or during the RSV season (typically October through March). Infants with prolonged birth hospitalizations due to prematurity or other causes should receive nirsevimab shortly before or promptly after discharge.
Infants younger than age 8 months born outside of the RSV season and older infants or toddlers at high risk who are recommended to receive nirsevimab in their second RSV season, should aim to receive nirsevimab shortly before the start of the RSV season (typically October).
If the ideal timing is missed, age-eligible infants and children who have not yet received a dose may be immunized at any time during the RSV season.
CDC has published an immunization information statement (IIS) for nirsevimab that is the equivalent of the vaccine information statement (VIS) for vaccines. Just as with a VIS, providers should give the IIS to the parent or caregiver before immunization and document it in the medical record.
Access the current nirsevimab IIS and translations in at least 24 languages from Immunize.org at: www.immunize.org/vaccines/vis/iis-rsv/.
Yes, you should report administration of nirsevimab to your state immunization information system (IIS, or “registry”) as you would report vaccine administration. Contact your state immunization program if you have specific questions about reporting to your state immunization information system.
It is important that all healthcare providers, both prenatal and pediatric, ensure that maternal RSV vaccination status is clearly documented and communicated. Prenatal care providers and birthing hospitals should ensure maternal RSV vaccination is reported to state immunization information systems (registries) and documented in maternal and newborn health records. It is also important to provide the pregnant person with a personal record of immunization.
Failure to document and communicate maternal RSV vaccination may result in extra work for pediatric offices and families to obtain records or in unnecessary administration of nirsevimab, at a retail cost of approximately $450 per dose.